Marta
Llanos Muñoz
Part Time Assistant Professor (Health Science)


Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublications in collaboration with researchers from Hospital Universitario Virgen del Rocío (13)
2024
-
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma
Modern Pathology, Vol. 37, Núm. 7
-
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
2022
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
European Thyroid Journal, Vol. 11, Núm. 5
2021
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2019
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2015
-
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400
2013
-
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787
2012
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819
2010
-
Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Blood, Vol. 116, Núm. 8